

Screening for Hemochromatosis in Asymptomatic Subjects With or Without a Family History

Lawrie W. Powell, MD, PhD; Jeannette L. Dixon, MPH; Grant A. Ramm, PhD; David M. Purdie, PhD; Douglas J. Lincoln, MBiostat; Gregory J. Anderson, PhD; V. Nathan Subramaniam, PhD; David G. Hewett, MD; Jeffrey W. Searle, MD; Linda M. Fletcher, PhD; Darrell H. Crawford, MD; Helen Rodgers, BSc; Katrina J. Allen, MD, PhD; Juleen A. Cavanaugh, PhD; Mark L. Bassett, MD

Background: Hemochromatosis in white subjects is mostly due to homozygosity for the common C282Y substitution in HFE. Although clinical symptoms are preventable by early detection of the genetic predisposition and prophylactic treatment, population screening is not currently advocated because of the discrepancy between the common mutation prevalence and apparently lower frequency of clinical disease. This study compared screening for hemochromatosis in subjects with or without a family history.

Methods: We assessed disease expression by clinical evaluation and liver biopsy in 672 essentially asymptomatic C282Y homozygous subjects identified by either family screening or health checks. We also observed a subgroup of untreated homozygotes with normal serum ferritin levels for up to 24 years.

Results: Prevalence of hepatic iron overload and fibrosis were comparable between the 2 groups. Disease-

related conditions were more common in male subjects identified by health checks, but they were older. Hepatic iron overload (grades 2-4) was present in 56% and 34.5% of male and female subjects, respectively; hepatic fibrosis (stages 2-4) in 18.4% and 5.4%; and cirrhosis in 5.6% and 1.9%. Hepatic fibrosis and cirrhosis correlated significantly with the hepatic iron concentration, and except in cases of cirrhosis, there was a 7.5-fold reduction in the mean fibrosis score after phlebotomy. All subjects with cirrhosis were asymptomatic.

Conclusions: Screening for hemochromatosis in apparently healthy subjects homozygous for the C282Y mutation with or without a family history reveals comparable levels of hepatic iron overload and disease. Significant hepatic fibrosis is frequently found in asymptomatic subjects with hemochromatosis and, except when cirrhosis is present, is reversed by iron removal.

Arch Intern Med. 2006;166:294-301

HFE-ASSOCIATED HEREDITARY hemochromatosis is one of the most common autosomal recessive conditions in individuals of northern European ancestry. The prevalence of the responsible mutation (C282Y) is approximately 1 in 10 for heterozygotes and 1 in 200 for homozygotes.¹ It is well established from cross-sectional population studies that between 60% and 80% of those at genetic risk will develop biochemical penetrance in the form of raised serum ferritin level and transferrin saturation.²⁻⁵ However, it is unclear how many people with biochemical penetrance will develop disease-related iron overload conditions such as cirrhosis and diabetes (clinical penetrance).^{5,6}

Genetic-based population screening for this disease is not widely advocated because it has been suggested that disease burden is low.² Others believe that it is an ideal disease to screen the population for

because the complications are preventable.⁵ However, the true risk of disease for those with the genetic predisposition has not been elucidated since most large studies have been cross-sectional and have not used clinical evaluation with liver biopsy to assess hepatic disease.^{2,4,7,8}

*For editorial comment
see page 269*

*CME course available at
www.archinternmed.com*

Alternatives to genetic-based population screening have been advocated, including family screening of hemochromatosis probands⁹ and population-based phenotypic screening.¹⁰ Bulaj and colleagues⁹ found that a substantial number of homozygous relatives of patients with hemochromatosis had unrecognized dis-

Author Affiliations are listed at the end of this article.

ease, and these researchers emphasized the importance of family screening. Other studies have also favored this method of identifying affected individuals.¹¹

Our present study aims to assess phenotypic expression of disease through clinical history, physical examination, serum iron indices, and liver biopsy findings in 672 apparently asymptomatic C282Y homozygotes, each identified through 1 of 2 different screening methods: (1) family screening of probands or (2) screening in primary medical practices. We also include long-term follow-up data on these individuals. Of the 672 homozygotes detected, 263 (39.1%) had significant hepatic iron loading (grades 3 or 4) and were thus at risk of long-term sequelae.⁶ Hepatic iron overload was as common in those identified by primary care physicians as in those identified by family screening. To our knowledge, this is the largest cohort of C282Y homozygotes yet described by clinical evaluation, hepatic histologic analysis, and longitudinal assessment.

METHODS

The study was approved by the ethics committee of each participating center. Written informed consent was obtained from all subjects.

STUDY GROUPS

Group 1 (Family Screening)

Screening for hemochromatosis was offered to relatives of 259 probands with proven C282Y-associated hemochromatosis. All available first-degree relatives were contacted and offered clinical assessment. Three relatives were previously diagnosed independently of their proband, but these were included in the analysis. A cohort of 401 subjects (200 male and 201 female) were identified as C282Y homozygotes and assessed.¹²⁻¹⁵ Proband were not included in further analysis for this study.

Group 2 (Clinical Health Check)

A total of 271 subjects (159 male and 112 female) were identified at health assessment examinations by primary care physicians either because they requested a routine health check ($n=234$ or 86.3%) or because they sought medical advice for minor ailments, specifically upper respiratory tract infections, headache, or backache ($n=37$ or 13.7%). Laboratory tests performed at the initial consultation included a standard multiple biochemical analysis, which included automated serum iron estimation. If the serum iron level was elevated, further investigations were carried out to establish or exclude C282Y homozygosity. Those subjects found to be homozygous were further evaluated for biochemical and clinical penetrance.

All subjects were genotyped for *HFE* mutations,¹⁴ some retrospectively because their diagnoses were made before 1996 and were based on HLA linkage and family studies.¹³⁻¹⁵

IRON STUDIES

Analyses and reference ranges for liver function tests, transferrin saturation, serum ferritin levels, and iron concentrations were as previously described.¹⁴⁻¹⁶ Liver biopsy specimens were assessed for iron content by histologic staining. Iron stores were graded from 0 to 4, as detailed by Searle et al,¹⁷ and

fibrosis was staged according to the scale first outlined by Scheuer¹⁸ (stage 4 equalling cirrhosis). The hepatic iron concentration (HIC) and hepatic iron index (HII) were also determined.¹⁵ Second liver biopsies were performed in 25 subjects after phlebotomy therapy was completed because of persistent elevation of liver enzymes or uncertainty about the presence of cirrhosis histologically.

CLINICAL EVALUATION OF SUBJECTS

All subjects were evaluated clinically by one of us (L.W.P., D.G.H., D.H.C., or M.L.B.) by means of a clinical history and physical examination, and relevant details including disease-related conditions were recorded. Alcohol consumption was assessed as previously described.^{16,19} A liver biopsy was performed in 350 subjects because of elevated serum ferritin levels (usually >500 $\mu\text{g/L}$), abnormal liver enzyme findings, hepatomegaly, or a combination of these; 239 biopsies (68.3%) were performed for diagnostic purposes before *HFE* gene testing became available. The clinical and laboratory data were analyzed by 2 biostatisticians (D.M.P. and D.J.L.) who had no knowledge of the subjects. Liver biopsy specimens were evaluated by a pathologist (J.W.S.) who had no knowledge of clinical details, and the degree of fibrosis was assessed on reticulin stains in which intrahepatic iron was not discernible. Hepatitis B antigens and antibodies against hepatitis C virus were sought using the AxSYM automated method (Abbott Laboratories, Abbott Park, Ill), and subjects testing positive for hepatitis B or C were excluded.

In a proportion of patients, we were able to assess the rate of iron accumulation in subjects with a rising serum ferritin level and also the histologic response to phlebotomy therapy. Subjects were divided into 2 pretreatment groups: those in whom the initial serum ferritin level was normal (nonexpressors, $n=114$) and those in whom it was elevated (expressors, $n=110$). Serum ferritin levels were observed serially in both groups until they showed a persistent rise or for periods up to 24 years. In the nonexpressors, if the level of serum ferritin rose above the normal range on at least 2 readings, phlebotomy was performed at weekly intervals until iron stores were depleted, as indicated by a transferrin saturation below 15% and/or a serum ferritin level of 20 $\mu\text{g/L}$ or lower. Total mobilizable storage iron was calculated by the method first described by Walters et al.²⁰ In the expressors, if the serum ferritin level rose progressively on at least 2 occasions, phlebotomy therapy was also performed, including calculation of total mobilizable storage iron. Those expressors without elevated serum alanine aminotransferase (ALT) levels (57 of 68 subjects) and those nonexpressors with serum ferritin levels that subsequently rose but without a rise in hepatic enzymes (54 of 55 subjects) were combined for statistical purposes. Of these 111 subjects, a total of 63 (25 male and 38 female) were observed for at least 6 months before phlebotomy was initiated (mean follow-up, 40.4 months; range of follow-up, 6.7-135.0 months). The progressive change in serum ferritin level was documented in these subjects.

STATISTICAL ANALYSIS

Statistical analysis was performed using the SPSS software package, version 13.0 (SPSS Inc, Chicago, Ill). Age, alcohol intake, and transferrin saturation values were compared between groups using the *t* test. Group differences for serum ferritin levels, HIC, and HII were calculated using the Wilcoxon rank-sum test. Comparisons of serum ferritin concentrations (or other variables that were not normally distributed) were performed using Mann-Whitney nonparametric tests. The frequencies of morbidity or disease symptoms were compared using χ^2 tests. In those sub-

Table 1. Clinical and Laboratory Findings in Homozygous Subjects

Characteristic	Subjects Identified Through Family Screening (Group 1)		Subjects Identified at Health Checks (Group 2)		P Value*	
	Male	Female	Male	Female	Male†	Female‡
	(n = 200)	(n = 201)	(n = 159)	(n = 112)		
Age, mean (range), y	38 (10-75)	44 (6-86)	42 (17-73)	44 (16-89)	<.01	.77
Alcohol consumption, mean (range) median, g/d	38 (3-120) 25	17 (3-100) 10	38 (3-150) 30	17 (1-100) 10	.94	.52
TS, mean (range), %	72 (12-100)	64 (7-100)	80 (21-100)	76 (29-100)	.001	<.001
SF, mean (10th-90th percentile range) median, µg/L	1014 (213-2173) 700	474 (55-970) 300	1325 (416-2699) 1000	628 (182-1147) 488	<.001	<.001
Subjects with ALT elevation, No. (%)	47 (24)	13 (7)	61 (38)	14 (13)	.002	.07
Disease-related clinical conditions, No. of subjects	49	20	58	16	NA	NA
Arthropathy	13	4	12	2		
Diabetes	4	7	5	5		
Hepatomegaly	29	5	32	8		
Hypogonadism	3	2	7	1		
Cardiac arrhythmia	0	2	2	0		
At least 1 disease-related condition, No. (%) of subjects	49 (24.5)	20 (9.9)	58 (36.5)	16 (14.3)	.01	.25
Liver biopsy, No.	111	74	111	54	.04	.09
Grade 2 iron	14	13	14	5		
Grade 3 iron	41	35	48	26		
Grade 4 iron	41	11	43	18		
HIC, mean (range) median, µmol/g dw	200 (9-766) 144	171 (6-700) 142	183 (16-598) 151	131 (1-327) 123	.89	.15
HII, mean (range) median	5.2 (0.2-17.4) 4.4	4.4 (0.1-14.3) 3.4	4.2 (0.5-12.0) 3.9	3.2 (0.1-8.3) 2.9	.18	.16
Fibrosis stage 2 or 3, No. of subjects	25	3	21	8	.51	.03
Cirrhosis, No. of subjects	7	2	13	4	.16	.21

Abbreviations: ALT, alanine aminotransferase; dw, dry weight; HIC, hepatic iron concentration; HII, hepatic iron index (HIC/age, y); NA, not applicable; SF, serum ferritin; TS, transferrin saturation.

*P values were derived from a *t* test for group differences for age and transferrin saturation, from a Mann-Whitney nonparametric test for alcohol intake, and from the Wilcoxon rank-sum test for group differences for serum ferritin level, HIC, and HII. P values were derived from either the Pearson χ^2 or Fisher test for group differences for categorical variables.

†Male subjects in group 1 compared with males in group 2.

‡Female subjects in group 1 compared with females in group 2.

jects without inflammation or elevated liver enzyme levels, the rise in serum ferritin concentration was calculated for each individual as the difference between the initial and final level and expressed relative to the intervening period in years. The degree of association between measures of iron load was measured using linear regression and Pearson correlation coefficient. Receiver operating characteristics (ROC) analysis was performed to identify the threshold of HIC and serum ferritin concentration for cirrhosis. All reported *P* values are 2 sided and *P* values of .05 or less are considered significant.

RESULTS

DISEASE EXPRESSION

Table 1 classifies the homozygous subjects according to how they were identified. Biochemical expression was higher in men in group 2, who were also older and had higher levels of serum ALT. Disease-related conditions were also more common in men from group 2. There was no significant difference in mean age between women in groups 1 and 2, and although not statistically significant, the serum transaminase levels were higher in women in group 2. However, we found comparable levels of HIC, hepatic fibrosis, and cirrhosis in subjects from each group. There was no significant difference in alcohol consump-

tion between the groups. Overall, biochemical expression of iron overload was present in 518 homozygotes (77%). Histologic hepatic iron overload (grades 2-4) was present in 56% of all male subjects (90.5% of males who underwent biopsy) and 34.5% of all females (84.4% of females who underwent biopsies). Stage 2 to 4 hepatic fibrosis was present in 18.4% and 5.4% of all male and female subjects, respectively (29.7% and 13.3%, respectively, of those who underwent biopsies), and cirrhosis was present in 5.6% of all males and 1.9% of all females. Of the 401 homozygotes in group 1, 54 (13.5%) had normal values for transferrin saturation levels.

The roles of age, HIC, and alcohol consumption as contributors to hepatic fibrosis and cirrhosis were assessed (**Table 2**). Both men and women with hepatic fibrosis and cirrhosis were older and had higher levels of serum ferritin, ALT, and HIC. The presence of fibrosis and cirrhosis when considered together was significantly associated with HIC and serum ferritin level for both men and women, but it did not correlate with alcohol intake. However, alcohol intake was higher in men with cirrhosis than in men without cirrhosis (*P* < .01). For women, the difference was not significant (*P* = .81).

All subjects with cirrhosis had HIC values greater than 200 µmol/g dry weight (dw) except for 3 men with heavy

Table 2. Factors Relevant to the Development of Fibrosis or Cirrhosis

Characteristic	Male Subjects		P Value	Female Subjects		P Value
	Stage 1 or No Fibrosis (n = 146)	Stages 2-4 Fibrosis (n = 67)		Stage 1 or No Fibrosis (n = 102)	Stages 2-4 Fibrosis (n = 17)	
Age, mean (range) median, y	40 (12-73) 39 (n = 146)	45 (15-75) 43 (n = 66)	<.01	42 (8-72) 41 (n = 102)	50 (30-77) 47 (n = 17)	.05
SF, mean (range) median, µg/L	927 (49-3516) 791 (n = 140)	2164 (126-5500) 1905 (n = 64)	<.001	555 (30-3600) 416 (n = 97)	1638 (323-3980) 1200 (n = 15)	<.001
ALT, mean (range) median, U/L	56 (5-180) 47 (n = 77)	92 (12-283) 72 (n = 49)	<.001	31 (10-81) 27 (n = 44)	47 (20-77) 51 (n = 9)	.02
Iron grade, No. of subjects	139	64	<.001	95	16	<.001
1	5	0		6	0	
2	23	6		17	1	
3	72	16		56	3	
4	40	41		16	12	
HIC, mean (range) median, µmol/g dw	168 (9-766) 131 (n = 114)	247 (41-525) 246 (n = 51)	<.001	143 (1-700) 126 (n = 82)	265 (75-518) 227 (n = 10)	.02
HII, mean (range) median	4.3 (0.2-16) 3.6 (n = 114)	5.8 (1.2-17.4) 5.2 (n = 51)	<.001	3.8 (0.1-14.3) 3.2 (n = 82)	5.0 (1.5-9.7) 4.3 (n = 10)	.17
Alcohol consumption, mean (range) median, g/d	36 (3-150) 20 (n = 92)	45 (3-150) 30 (n = 50)	.13	22 (5-100) 10 (n = 32)	18 (5-50) 10 (n = 9)	.85

Abbreviations: ALT, alanine aminotransferase; dw, dry weight; HIC, hepatic iron concentration; HII, hepatic iron index (HIC/age, y); NA, not applicable; SF, serum ferritin.

alcohol intake. When the 2 groups were combined, ROC curve analysis showed that a HIC of 236 µmol/g dw demonstrated optimal sensitivity (80%) and specificity (78%) in distinguishing patients with cirrhosis from those with no cirrhosis (area under the curve [AUC], 0.86; 95% confidence interval [CI], 0.8-0.91; $P < .001$) (**Figure 1A**). For serum ferritin, ROC curve analysis was performed, excluding subjects with alcohol ingestion of more than 60 g/d for men and more than 50 g/d for women and also subjects with serum ALT levels greater than 60 U/L for men and women. The results showed that a serum ferritin level of 1653 µg/L demonstrated optimal sensitivity (90%) and specificity (92%) for cirrhosis (AUC, 0.96; 95% CI, 0.92-1.0; $P < .001$) (Figure 1B). In this analysis, a serum ferritin level of 1000 µg/L gave 100% sensitivity but 77% specificity.

LONGITUDINAL ASSESSMENT

Since no significant difference was detected between groups 1 and 2 with respect to HIC, the 2 groups were combined for analysis of longitudinal aspects of the effects of iron accumulation. In 114 subjects (17%; 31 male, 83 female), the initial serum ferritin value was normal (nonexpressors). In 47 (41.2%) of these (10 male, 37 female) there was no rise in serum ferritin level for periods up to 24 years (mean follow-up, 56.8 months; range, 2 months to 23.6 years). A progressive rise in serum ferritin level was observed in 55 subjects (48.2%; 17 male, 38 female), while 12 subjects (10.5%; 4 male, 8 female) were lost to follow-up.

A rise in serum ferritin level was observed in 68 of the 110 subjects (37 male, 31 female) with elevated initial serum ferritin levels (expressors). The expressors and non-expressors with a rise in serum ferritin level were combined for analysis. The levels fluctuated in subjects with raised liver enzyme levels, and subjects with serum ALT

levels greater than 60 U/L were excluded from the longitudinal analysis. In 63 subjects observed for at least 6 months, the mean (SE) rise in serum ferritin level was 76.5 (21.0) µg/L per year for men and 62.3 (15.8) µg/L per year for women. The mean (SE) ages of these subjects at the end of the observation period were 35.2 (3.4) years for men and 46.7 (2.3) years for women. Correlation of serum ferritin levels and mobilizable body iron over a wide range of body iron stores in subjects who underwent phlebotomy therapy indicates that a rise of 1 µg/L of serum ferritin concentration represents 3.3 mg of storage iron (**Figure 2**). In the subjects observed, this equates to a mean body iron accumulation of 0.25 g/y in men and 0.21 g/y in women (ie, 0.68 and 0.57 mg/d, respectively). At this rate, if iron accumulation is linear, the time to reach a critical level of HIC for the development of cirrhosis (236 µmol/g dw) would be approximately 20.4 years after the serum ferritin rises to abnormal levels in men and 21 years in women (**Figure 3**).²¹⁻²³

RELATIONSHIP OF SERUM FERRITIN TO STAGE OF FIBROSIS

Table 3 outlines the relationship of serum ferritin level to the stage of hepatic fibrosis in subjects, excluding those with serum ALT levels greater than 60 U/L. The mean age of the subjects increased with each increment of serum ferritin level to 2000 µg/L, and advanced fibrosis and cirrhosis were more common with high levels of serum ferritin. No case of cirrhosis was detected in subjects with a serum ferritin level of 1000 µg/L or lower.

SUBJECTS WITH REPEATED LIVER BIOPSY

Twenty five subjects underwent a second liver biopsy after completion of phlebotomy to remove uncertainty about the presence of cirrhosis or to investigate the cause of




Figure 1. Receiver operating characteristic (ROC) curves. A, The ROC for hepatic iron concentration threshold distinguishes hemochromatosis patients with cirrhosis from those with no cirrhosis (area under the curve [AUC], 0.86; 95% confidence interval [CI], 0.80-0.91; $P < .001$). B, The ROC curve for serum ferritin threshold distinguishes hemochromatosis patients with cirrhosis from those with no cirrhosis (excluding all subjects with alcohol intake >60 g/d [men] and >50 g/d [women] and serum aminotransferase level >60 U/L [men and women]) (AUC, 0.96; 95% CI, 0.92-1.00; $P < .001$).

persistently abnormal liver enzyme levels. In all cases, except where cirrhosis was present, the fibrosis score improved significantly following removal of iron. In 15 of the 19 subjects without heavy alcohol intake, the fibrosis completely reversed, and in 4, it was reduced to stage 1 (**Figure 4**). When the 5 men with significant alcohol intake (>60 g/d) were excluded, the mean (SD) fibrosis score decreased from 1.95 (0.85) to 0.26 (0.45) ($P < .001$).

COMMENT

Population screening for hemochromatosis is not currently advocated owing to uncertainty about the natural history of the disease and the apparent discrepancy between the mutation frequency and clinical disease. For this reason, current interest is focused on optimal methods for detection of early disease. The present systematic study compares screening of family members of C282Y homozygous probands with screening of appar-

ently healthy subjects by primary care physicians. Furthermore, this is the largest study to date of clinical, biochemical, and histologic penetrance in C282Y homozygotes detected by screening and reports longitudinal data including a proportion of untreated individuals observed for up to 24 years.

We found comparable levels of HIC, hepatic fibrosis, and cirrhosis in subjects from each group (Table 1). Fibrosis of stage 2 or higher was present in 66 male subjects (18.4% of males overall and 29.7% of those undergoing biopsies) and 17 female subjects (5.4% of females overall and 13.3% of those undergoing biopsy). Cirrhosis was present in 5.6% of all men and 1.9% of all women, and all were asymptomatic. Thus, significant hepatic fibrosis is common in asymptomatic homozygous subjects, and clinically silent cirrhosis may also be present. In all subjects who underwent a second liver biopsy after phlebotomy therapy, the fibrosis score improved, except in cases of cirrhosis, and in 15 of 19 subjects, the fibrosis completely reversed. Niederau et al⁶ noted that fibrosis improved in 21 of 23 subjects who underwent repeated liver biopsies, but the specific staging of fibrosis was not documented.

Our findings in relatives are similar to those of Bulaj et al.⁹ In our study, 29.8% of men and 11.5% of women were found to have at least 1 disease-related condition. We acknowledge, however, that in the absence of controls, it is difficult to know what proportions of the arthropathy, diabetes, or other conditions are attributable to hemochromatosis. In addition, while the subjects with cirrhosis in our study were asymptomatic, they were at risk of complications, including variceal hemorrhage, hepatic decompensation, and hepatocellular carcinoma. Thus, cross-sectional studies^{2,4,7,8,24-26} may well have overlooked asymptomatic but potentially lethal disease that becomes evident only by clinical and liver biopsy evaluation.

There is compelling evidence from our findings and also from others^{6,9,27} that clinical features of hemochromatosis and hepatic fibrosis and cirrhosis are related to HIC. We found that the presence of fibrosis and cirrhosis correlated significantly with HIC but not with alcohol intake. However, alcohol intake was higher in men with cirrhosis than in men without cirrhosis, confirming the findings of Fletcher et al¹⁹ that excess alcohol ingestion increases the risk of extension of hepatic fibrosis to cirrhosis. The critical threshold of HIC leading to cirrhosis has been reported at a 7- to 10-fold increase above normal.^{15,28,29} In the present study HIC greater than 200 $\mu\text{mol/g dw}$ (>5 times normal) was significantly associated with hepatic fibrosis and cirrhosis (excluding 3 men with heavy alcohol intake). Coexisting diseases, including porphyria cutanea tarda and steatohepatitis, may accelerate liver injury and fibrosis,⁹ but these were not analyzed systematically in our study.

In the present study there was nonexpression of disease in 17% of all subjects for periods up to 24 years. Similar observations have been made by others.^{24,26,30} It is possible that factors such as multiple blood donations and blood loss may account for this, but these were not compared in expressors vs nonexpressors. However, in our study, expressing male subjects were older than nonexpressors ($P < .001$) and had a higher alcohol intake ($P < .05$).




Figure 2. The relationship between serum ferritin level and mobilizable iron in 328 subjects who underwent phlebotomy.




Figure 3. Calculations used to derive the number of years to reach the critical hepatic iron (Fe) threshold of 236 µmol/g dry weight (dw) that defines cirrhosis. A indicates the number of grams of iron present in an adult liver, equivalent to 236 µmol/g dw, where $A = B \times C \times D \times E$. B indicates the critical hepatic iron threshold of 236 µmol/g dw that defines cirrhosis; C, the molecular weight of iron (56 g/mol); D, the average liver weight (1800 g for men, 1400 g for women)²¹; and E, the conversion factor for liver dw to wet liver weight (0.25).²² F indicates the average iron content of a normal liver (0.8 g for men, 0.3 g for women)²³; G, the rate of iron accumulation, where $G = H \times I$; H, the mean rise in serum ferritin level (76.5 µg/L per year for men, 62.3 µg/L per year for women [see the “Results” section]); and I, the number of grams of iron corresponding to a rise in serum ferritin concentration of 1 µg/L (3.3 mg) (Figure 2). Thus, for men, $G = 76.5 \times (3.3 \times 10^{-3}) = 0.25 \text{ g/y}$; for women, $G = 62.3 \times (3.3 \times 10^{-3}) = 0.21 \text{ g/y}$ (see the “Results” section).

In the absence of inflammation, the best noninvasive marker of HIC is the serum ferritin level.^{12,13,20,26,27,31-33} We found that for each 1 µg/L rise in serum ferritin level, body iron content rose by approximately 3.3 mg. The notable

difference between our findings with respect to serum ferritin levels over time and those of other recent studies^{24,26,30} may be explained by the effect of inflammation and hepatic injury, which were specifically analyzed in

Table 3. Relationship of Serum Ferritin Level to Stage of Fibrosis in 256 Subjects*

Serum Ferritin Level, $\mu\text{g/L}$	Age, Mean (SE), y	Fibrosis Stage, No. (%) of Patients				
		0	1	2	3	4
<500 (n = 93)	37.1 (1.6)	83 (89)	6 (7)	4 (4)	0	0
500-1000 (n = 95)	41.8 (1.3)	68 (72)	16 (17)	8 (8)	3 (3)	0
1001-2000 (n = 50)	46.0 (1.7)	25 (50)	8 (16)	11 (22)	4 (8)	2 (4)
2001-3000 (n = 11)	54.7 (3.4)	2 (18)	3 (27)	1 (9)	1 (9)	4 (36)
>3000 (n = 7)	54.7 (3.4)	1 (14)	0	2 (29)	0	4 (57)

*Subjects with alanine aminotransferase levels higher than 60 U/L were excluded.




Figure 4. Reduction in fibrosis following phlebotomy therapy. Twenty-five subjects underwent a second liver biopsy after phlebotomy. Five subjects were excluded from analysis owing to significant alcohol intake (>60 g/d). In the remaining 20 subjects, the fibrosis score improved significantly following removal of iron by phlebotomy except where cirrhosis was present.

our study. Our estimate of the rate of iron accumulation with age indicates that the mean age of homozygotes whose health could be adversely affected by HIC greater than $236 \mu\text{mol/g dw}$ would be approximately 21 years after the hepatic iron stores begin to increase in both men and women. However, not all homozygous subjects who reach a HIC of $236 \mu\text{mol/g dw}$ develop cirrhosis, indicating the importance of other environmental and genetic factors that may modify tissue damage. These include mutations in other genes involved in iron metabolism, such as hepcidin,³⁴⁻³⁶ hemojuvelin,³⁷ and other iron regulatory genes.³⁸⁻⁴⁰

In conclusion, we found that screening for hemochromatosis in the primary care setting and family screening reveal comparable levels of hepatic fibrosis and cirrho-

sis. Previously unidentified asymptomatic homozygotes are at a definite risk of iron overload-related hepatic fibrosis and cirrhosis, which, if diagnosed in the precirrhotic stage, can be reversed by iron removal by phlebotomy. Screening for hemochromatosis should not be confined to relatives of probands with disease.

Accepted for Publication: September 19, 2005.

Author Affiliations: Queensland Institute of Medical Research (Drs Powell, Ramm, Purdie, Anderson, and Subramaniam, Ms Dixon, and Mr Lincoln), Departments of Gastroenterology and Hepatology (Dr Hewett) and Anatomical Pathology (Dr Searle), Royal Brisbane & Women's Hospital, and Department of Gastroenterology and Hepatology, Princess Alexandra Hospital (Drs Fletcher and

Crawford), Brisbane, Australia; the Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, Australia (Dr Allen); and Departments of Gastroenterology (Ms Rodgers and Dr Bassett) and Medical Genetics (Dr Cavanaugh), Canberra Hospital, and the Australian National University (Drs Cavanaugh and Bassett), Canberra, Australia.

Correspondence: Lawrie W. Powell, MD, PhD, Centre for the Advancement of Clinical Research, Royal Brisbane & Women's Hospital, Brisbane, Queensland 4029, Australia (Lawrie.Powell@qimr.edu.au).

Author Contributions: Drs Powell and Ramm and Ms Dixon contributed equally to this article. Dr Powell, as principal author, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Financial Disclosure: None.

Funding/Support: This research was supported by grant 339400 from the National Health and Medical Research Council of Australia, grant 5R01DK057648-02 from the National Institutes of Health (Drs Powell, Ramm, Anderson, and Subramaniam), and The Canberra Hospital Private Practice Fund (Drs Cavanaugh and Bassett).

Previous Presentations: Aspects of this work were presented at the Annual Scientific Meeting of the American Association for the Study of Liver Diseases; October 2003 and 2004; Boston, Mass.

Acknowledgment: Tamara Pereria, PhD, assisted with the generation of the ROC curve analyses.

REFERENCES

1. Bacon BR, Powell LW, Adams PC, Kresina TF, Hoofnagle JH. Molecular medicine and hemochromatosis: at the crossroads. *Gastroenterology*. 1999;116:193-207.
2. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis mutation in the USA. *Lancet*. 2002;359:211-218.
3. Olynyk JK, Cullen DJ, Aquilina S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. *N Engl J Med*. 1999;341:718-724.
4. Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. *N Engl J Med*. 2005;352:1769-1778.
5. Delatycki MB, Allen KJ, Nisselle AE, et al. Use of community screening to prevent HFE-associated hereditary haemochromatosis. *Lancet*. 2005;366:314-316.
6. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. *Gastroenterology*. 1996;110:1107-1119.
7. Asberg A, Hveem K, Thorstensen K, et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. *Scand J Gastroenterol*. 2001;36:1108-1115.
8. Milman N, Pedersen P, Ovesen L, Melsen GV, Fenger K. Frequency of the C282Y and H63D mutations of the hemochromatosis gene (HFE) in 2501 ethnic Danes. *Ann Hematol*. 2004;83:654-657.
9. Bulaj ZJ, Ajoika RS, Phillips JD, et al. Disease-related conditions in relatives of patients with hemochromatosis. *N Engl J Med*. 2000;343:1529-1535.
10. Adams PC, Kertesz AE, McLaren CE, Barr R, Bamford A, Chakrabarti S. Population screening for hemochromatosis: a comparison of unbound iron-binding capacity, transferrin saturation, and C282Y genotyping in 5,211 voluntary blood donors. *Hepatology*. 2000;31:1160-1164.
11. Bradley LA, Haddow JE, Palomaki GE. Population screening for haemochromatosis: expectations based on a study of relatives of symptomatic probands. *J Med Screen*. 1996;3:171-177.
12. Halliday JW, Russo AM, Cowlshaw JL, Powell LW. Serum ferritin in diagnosis of hemochromatosis. *Lancet*. 1977;2:621-623.
13. Bassett ML, Halliday JW, Ferris RA, Powell LW. Diagnosis of hemochromatosis

- in young subjects: predictive accuracy of biochemical screening tests. *Gastroenterology*. 1984;87:628-633.
14. Jazwinska EC, Cullen LM, Busfield F, et al. Haemochromatosis and HLA-H. *Nat Genet*. 1996;14:249-251.
15. Bassett ML, Halliday JW, Powell LW. Value of hepatic iron measurements in early haemochromatosis and determination of the critical iron concentration associated with fibrosis. *Hepatology*. 1986;6:24-29.
16. Leggett BA, Halliday JW, Brown NN, Powell LW. Prevalence of hemochromatosis amongst asymptomatic Australians. *Br J Haematol*. 1990;74:525-530.
17. Searle JW, Kerr JFR, Halliday JW, Powell LW. Iron storage disease. In: MacSween RM, Anthony PP, Scheuer PJ, eds. *Pathology of the Liver*. 2nd ed. Edinburgh, Scotland: Churchill Livingstone; 1987:257-272.
18. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. *J Hepatol*. 1991;13:372-374.
19. Fletcher LM, Dixon JL, Purdie DM, Powell LW, Crawford DH. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. *Gastroenterology*. 2002;122:281-289.
20. Walters GO, Miller FM, Worwood M. Serum ferritin concentration and iron stores in normal subjects. *J Clin Pathol*. 1973;26:770-772.
21. Wanless IR. Physioanatomic considerations. In: Schiff ER, Sorrell MF, Maddrey WC, eds. *Schiff's Diseases of the Liver*. 8th ed. Philadelphia, Pa: Lippincott-Raven Publishers; 1993:3-37.
22. Worwood M. Laboratory determinants of iron status. In: Brock JH, Halliday JW, Pippard MJ, Powell LW, eds. *Iron Metabolism in Health and Disease*. London, England: WB Saunders & Co; 1994:449-476.
23. Bothwell TH, Charlton RW, Cook JD, Finch CA. *Iron Metabolism in Man*. Oxford, England: Blackwell Scientific Publications; 1979:89.
24. Andersen RV, Tybjaerg-Hansen A, Appleyard M, Birgens H, Nordestgaard BG. Hemochromatosis mutations in the general population: iron overload progression rate. *Blood*. 2004;103:2914-2919.
25. Milman N, Pedersen P, a Steig T, Byg KE, Graudal N, Fenger K. Clinically overt hereditary hemochromatosis in Denmark 1948-1985: epidemiology, factors of significance for long-term survival, and causes of death in 179 patients. *Ann Hematol*. 2001;80:737-744.
26. Olynyk JK, Hagan SE, Cullen DJ, Beilby J, Whittall DE. Evaluation of untreated hereditary hemochromatosis in the Busselton population: a 17-year study. *Mayo Clin Proc*. 2004;79:309-313.
27. Adams PC, Deugnier Y, Moirand R, Brissot P. The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. *Hepatology*. 1997;25:162-166.
28. Adams PC. Is there a threshold of hepatic iron concentration that leads to cirrhosis in C282Y hemochromatosis? *Am J Gastroenterol*. 2001;96:567-569.
29. Sallie RW, Reed WD, Shilkin KB. Confirmation of the efficacy of hepatic tissue iron index in differentiating genetic haemochromatosis from alcoholic liver disease complicated by alcoholic haemosiderosis. *Gut*. 1991;32:207-210.
30. Yamashita C, Adams PC. Natural history of the C282Y homozygote for the hemochromatosis gene (HFE) with a normal serum ferritin level. *Clin Gastroenterol Hepatol*. 2003;1:388-391.
31. Leggett BA, Brown NN, Bryant SJ, Duplock L, Powell LW, Halliday JW. Factors affecting the concentrations of ferritin in serum in a healthy Australian population. *Clin Chem*. 1990;36:1350-1355.
32. Morrison ED, Brandhagen DJ, Phatak PD, et al. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. *Ann Intern Med*. 2003;138:627-633.
33. Guyader D, Jacquelinet C, Moirand R, et al. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. *Gastroenterology*. 1998;115:929-936.
34. Merryweather-Clarke AT, Cadet E, Bomford A, et al. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. *Hum Mol Genet*. 2003;12:2241-2247.
35. Papanikolaou G, Samuels ME, Ludwig EH, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. *Nat Genet*. 2004;36:77-82.
36. Jacolot S, Le Gac G, Scotet V, Quere I, Mura C, Ferec C. HAMP as a modifier gene that increases the phenotypic expression of the HFE pC282Y homozygous genotype. *Blood*. 2004;103:2835-2840.
37. Le Gac G, Scotet V, Ka C, et al. The recently identified type 2A juvenile hemochromatosis gene (HJV), a second candidate modifier of the C282Y homozygous phenotype. *Hum Mol Genet*. 2004;13:1913-1918.
38. Fargion S, Valenti L, Dongiovanni P, Fracanzani AL. TNFalpha promoter polymorphisms. *Methods Mol Med*. 2004;98:47-58.
39. Stickel F, Oesterreicher CH, Datz C, et al. Prediction of progression to cirrhosis by a glutathione S-transferase P1 polymorphism in subjects with hereditary hemochromatosis. *Arch Intern Med*. 2005;165:1815-1817.
40. Oesterreicher CH, Datz C, Stickel F, et al. TGF-beta1 codon 25 gene polymorphism is associated with cirrhosis in patients with hereditary hemochromatosis. *Cytokine*. 2005;31:142-148.